用于人类流感病毒抗原性表征的ViroSpot微量中和试验
血凝抑制试验长期用于流感病毒抗原性表征,但多数近期季节性甲型H3N2流感病毒已丧失凝集红细胞的能力,且其他H3N2毒株的血凝活性通常对神经氨酸酶抑制剂奥司他韦敏感,提示血凝活性由神经氨酸酶而非血凝素负责,这使H3N2疫苗株的抗原性表征与选择变得复杂。本文描述ViroSpot微量中和试验的开发与应用,作为血凝抑制试验的可靠稳健替代方法,通过自动化读取免疫染色细胞单层测定血清中和,并可用该试验对抗原性表征此前无法凝集红细胞的流行性甲型H3N2毒株。
要点
- 多数近期季节性甲型H3N2流感病毒已丧失凝集红细胞能力,血凝抑制试验难以用于其抗原性表征。
- ViroSpot微量中和试验通过自动化读取免疫染色细胞单层测定血清中和,可作为血凝抑制试验的替代方法。
- 该试验对感染性病毒测试剂量的变异相对不敏感,并兼容标准化大规模分析。
核心结论
- ViroSpot微量中和试验是血凝抑制试验的可靠稳健替代方法,可用于抗原性表征无法凝集红细胞的流行性甲型H3N2流感毒株。
研究设计与样本
- 本文描述ViroSpot微量中和试验的开发与应用,以自动化读取免疫染色细胞单层测定血清中和,其格式设计旨在尽量减少感染性病毒剂量对血清中和滴度的影响。
主要发现
- 血清中和 largely 独立于病毒复制速率和细胞间传播,便于不同病毒分离株的比较。
- ViroSpot微量中和试验的其他优势包括对感染性病毒测试剂量的变异相对不敏感、自动化捕获与分析残余感染模式,以及兼容标准化大规模分析。
- 使用该试验可对抗原性表征此前无法凝集红细胞的多种流行性甲型H3N2毒株。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The hemagglutination inhibition (HI) assay has been used for the antigenic characterization of influenza viruses for decades. However, the majority of recent seasonal influenza A viruses of the H3N2 subtype has lost the capacity to agglutinate erythrocytes of various species. The hemagglutination (HA) activity of other A(H3N2) strains is generally sensitive to the action of the neuraminidase inhibitor oseltamivir, which indicates that the neuraminidase and not the hemagglutinin is responsible for the HA activity. These findings complicate the antigenic characterization and selection of A(H3N2) vaccine strains, calling for alternative antigenic characterization assays. Here we describe the development and use of the ViroSpot microneutralization (MN) assay as a reliable and robust alternative for the HI assay. Serum neutralization of influenza A(H3N2) reference virus strains and epidemic isolates was determined by automated readout of immunostained cell monolayers, in a format designed to minimize the influence of infectious virus doses on serum neutralization titers. Neutralization of infection was largely independent from rates of viral replication and cell-to-cell transmission, facilitating the comparison of different virus isolates. Other advantages of the ViroSpot MN assay include its relative insensitivity to variation in test dose of infectious virus, automated capture and analyses of residual infection patterns, and compatibility with standardized large scale analyses. Using this assay, a number of epidemic influenza A(H3N2) strains that failed to agglutinate erythrocytes, were readily characterized antigenically.
引用
- van Baalen CA, Jeeninga RE, Penders GH, et al. ViroSpot microneutralization assay for antigenic characterization of human influenza viruses. Vaccine. 2016. PMID: 27899226. doi:10.1016/j.vaccine.2016.11.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。